Impact of the immune profiles of hypertensive patients with and without obesity on COVID-19 severity
Authors' conclusion
Our findings suggest that clinical and immune variables and obesity interact synergistically to increase the COVID-19 progression risk. The immune signatures of hypertensive patients with and without obesity severe COVID-19 highlight differences in immune dysregulation mechanisms, with potential therapeutic applications.
Study context
- Population
- Hypertensive adults hospitalized with COVID-19, multicenter registry
- Participants
- 213 adults
- Exposure
- Hypertensive patients with obesity vs without obesity
- Obesityn = 89
- No obesityn = 124reference
- Outcome
- Clinical and immune profiles (46 immune markers)
Methodological detailsmulticenter registry
- Multicenter registry
Main finding
As reported in the abstract
- Patients with obesity were younger and fewer had cardiac disease and myocardial injury
- Obesity: higher EGF, GCSF, GMCSF, IL-1ra, IL-5, IL-7, IL-8, IL-15, IL-1β, MCP 1 and VEGF levels, total lymphocyte counts and CD8+ CD38+ mean fluorescence intensity (MFI)
- Obesity: lower NK-NKG2A MFI and percentage of CD8+ CD38+ T cells
- Significant correlations between cytokine and immune cell expression in both groups
Observational data: associations, not effects.
Further findings
Predictors of progression to severe COVID-19 (logistic regression)
- Obesity: diabetes, EGF, IL-10 and IL-13 levels, and percentage of CD8+ HLA-DR+ CD38+ cells
- 5 variables
- No obesity: myocardial injury and percentages of B lymphocytes and HLA-DR+ CD38+ cells
- 3 variables
Original publication
Impact of the immune profiles of hypertensive patients with and without obesity on COVID-19 severity. Int J Obes (Lond). Published 6 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →